<DOC>
	<DOCNO>NCT01627717</DOCNO>
	<brief_summary>Infection HIV hepatitis C virus ( HCV ) frequent due similar transmission mode . Near 20 % people live HIV also infect HCV . People live HIV treat anti-HIV medication may interact numerous medication , include new medication HCV . Boceprevir one new HCV medication consider part standard care people infect HCV . Previous research show boceprevir may influence capacity liver breakdown ( metabolize ) certain medication medication use combination boceprevir , blood concentration may increase decrease could increase risk side effect decrease efficacy . Among drug potential interaction boceprevir maraviroc , anti-HIV medication . If concentration maraviroc increase , people may experience side effect . However , concentration maraviroc decrease , people live HIV may lower suppression virus . This could increase risk HIV virus develop resistance , treatment longer effective . No study conduct investigate effect boceprevir blood concentration maraviroc . This research project address research question . This project , however , do people live HIV since resistance may develop people concentration maraviroc decrease . It reason investigator wish recruit healthy people infect HIV HCV . Eleven healthy volunteer include . They receive maraviroc 150 mg ( 1 tablet ) every 12 hour day 1 19 inclusively . On day 5 , total ten blood sample draw follow 12 hour ( 0 , 0.5 , 1 , 1.5 , 2 , 3 , 4 , 5 , 6 , 8 12 hour maraviroc morning dose intake ) measure blood concentration maraviroc . Boceprevir 800 mg ( 4 capsule ) every 8 hour food start day 6 continue day 19 inclusively . On day 19 , morning maraviroc boceprevir dose , another ten blood sample draw 12 hour period . A phone follow-up do day 26 . Thus , total study duration subject 26 day . The investigator compare blood concentration maraviroc give alone blood concentration maraviroc give boceprevir .</brief_summary>
	<brief_title>The Effects Direct Acting Antiviral Agent Boceprevir Pharmacokinetics Maraviroc Healthy Volunteers</brief_title>
	<detailed_description>Co-infection human immunodeficiency virus ( HIV ) hepatitis C virus ( HCV ) frequent share mode viral transmission . Near 20 % HIV-infected patient also infect HCV , prevalence HCV HIV population vary accord route transmission . Despite decrease mortality morbidity HIV-infected individual since introduction potent combination antiretroviral therapy ( cART ) , HCV-related end-stage liver disease ( ESLD ) represent leading cause death patient . HCV treatment outcomes term sustain virologic response ( SVR ) usually bad co-infected patient , pegylated interferon-alpha ( PEG IFN-alpha ) / ribavirin treatment lead success 40 50 % mono-infected patient 30 % co-infected patient . In patient co-infected HIV , present guideline recommend fixed course PEG IFN-alpha / ribavirin 48 week optimize HCV treatment . The recent introduction boceprevir telaprevir , two direct act antiviral agent ( DAAs ) HCV , change standard care treatment chronic HCV infection genotype 1 , whereby AASLD practice guideline recommend use boceprevir telaprevir combination PEG IFN-alpha/ribavirin HCV mono-infected treatment na誰ve experience patient . No study yet publish HCV-HIV co-infected patient . Boceprevir novel HCV NS3 serine protease inhibitor ( PI ) . In clinical study treatment-na誰ve experienced patient , agent , combination standard care ( PEG IFN-alpha/ribavirin ) , achieve much great SVR rate , reach rate higher 70 % clinical study . Boceprevir take 800 mg ( four 200 mg capsule ) three time day ( every 7-9 hour ) food . Boceprevir usually well tolerated accord single multiple dose pharmacokinetics study healthy volunteer adverse effect similar placebo . The serious adverse effect relate boceprevir see boceprevir coadministered PEG-IFN alpha/ribavirin . These include anemia , neutropenia thrombocytopenia . An interim analysis randomize double-blind placebo-controlled study use boceprevir/PEG IFN-alpha/ribavirin HCV treatment na誰ve HCV/HIV co-infected patient show 70.5 % patient boceprevir/PEG IFN-alpha/ribavirin undetectable HCV RNA 24 week compare 34.4 % patient PEG IFN-alpha/ribavirin . Boceprevir metabolism mediate mainly aldo-keto reductase CYP3A4 CYP3A5 . Boceprevir also substrate p-glycoprotein ( P-gp ) . Boceprevir know strong inhibitor CYP3A4/3A5 drug metabolize pathway may increase exposure administer product . In vitro data show boceprevir induce CYP3A4/5 . Surprisingly , however , recent warning FDA ( FDA Medwatch , February 9th 2012 ) Dear Health Care Professional Letter Merck &amp; Co , Inc. ( USA ) reveal boceprevir decrease exposure HIV ritonavir-boosted protease inhibitor CYP3A4 substrates . This unpublished data suggest boceprevir vivo may act CYP3A4 inducer . Contradictory vitro vivo drug interaction study result uncommon . The clinical impact interaction moment unclear . This implication possible drug-drug interaction boceprevir use combination cART HIV/HCV co-infected patient . Among antiretroviral drug seem promise use HIV/HCV co-infected patient maraviroc . A recent conference abstract suggest add maraviroc antiretroviral regimen HIV/HCV-co-infected patient na誰ve anti-HCV therapy decrease liver fibrosis . Maraviroc usually give 300 mg twice daily without food dose may change depend patient 's concomitant medication . Maraviroc inhibit major CYP450 enzyme ( CYP1A2 , CYP2B6 , CYP2C8 , CYP2C9 , CYP2C19 , CYP2D6 CYP3A4 ) show effect plasma concentration molecule . Maraviroc 's major metabolic route oxidation N-dealkylation vitro study demonstrate maraviroc primarily metabolize CYP3A4 . Concomitant use maraviroc know CYP3A4 inhibitor require maraviroc dosage reduce 150 mg twice day use CYP3A4 inducer necessitate maraviroc use 600 mg twice daily . Maraviroc well tolerate various clinical trial drop-out rate 4 6 % similar placebo . The common side effect upper respiratory tract infection ( 22,8 % ) , cough ( 13,8 % ) , fever ( 12,9 % ) , rash ( 10,8 % ) , muscle-related symptom ( 9,9 % ) , dizziness postural dizziness ( 8,7 % ) , abdominal pain ( 8.2 % ) , insomnia ( 7,7 % ) constipation ( 5,9 % ) ( 19 ) . Maraviroc use caution patient increase risk cardiovascular event case myocardial infarction , postural hypotension syncope report . Postural hypotension dose-related unlikely occur label dos . However , postural hypotension may concern drug-drug interaction occur without proper dose adjustment maraviroc . The use maraviroc 150 mg BID steady-state drug-drug interaction study healthy volunteer presence potent CYP3A4 inhibitor well tolerate . No study regard use maraviroc boceprevir conduct . Given similar metabolic route take molecule , CYP3A4 , likely molecule interact . It unknown boceprevir increase decrease maraviroc systemic exposure . To limit potential toxicity study discontinuation , however , choose study maraviroc 150 mg twice daily . The study evaluate effect boceprevir pharmacokinetics maraviroc healthy volunteer . As maraviroc inhibit induce CYP 450 isoenzymes , maraviroc expect influence boceprevir pharmacokinetics . For reason , choose measure boceprevir concentration . This phase 1 , single center , open-label , crossover single-sequence drug-drug interaction study healthy Caucasian male . The study population limit Caucasian male limit interpatient pharmacokinetic variability . Eleven healthy volunteer include . They receive maraviroc 150 mg every 12 hour day 1 19 inclusively . On day 5 , 12 hour intensive pharmacokinetic sample do measure maraviroc absence boceprevir . Boceprevir 800 mg every 8 hour food start day 6 continue day 19 inclusively . On day 19 , 12 hour intensive pharmacokinetic sampling repeat measure maraviroc concentration presence boceprevir . The maraviroc concentration steady-state day 5 . Furthermore , 14 day boceprevir sufficient study inhibition induction . A phone follow-up do day 26 . Thus , total study duration subject 26 day . The primary objective study evaluate effect boceprevir pharmacokinetics maraviroc healthy volunteer . The secondary objective determine appropriate maraviroc dose take give concomitantly boceprevir .</detailed_description>
	<mesh_term>Maraviroc</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Caucasian male healthy individual base history/physical examination laboratory evaluation ( outofrange result hematology test ( hemoglobin ( Hb ) &gt; 130 g/L men ; absolute neutrophil count ( ANC ) &gt; 2000 cells/uL ; platelet &gt; 159 x 109/L ) , biochemistry ( AST &lt; 35 IU/L , ALT &lt; 40 , IU/L , alkaline phosphatase &lt; 100 IU/L , total bilirubin &lt; 17 umol/L , lipase &lt; 45 IU/L , creatinine &lt; 120 umol/L , normal coagulation test ( INR &lt; 1.2 , aPPT &lt; 40 second ) urinalysis . LDLcholesterol &lt; /= 5 mmol/L , triglyceride &lt; /= 1.7 mmol/L 10 year estimate cardiovascular ( CV ) disease risk &lt; /= 10 % ( `` low risk '' ) per Framingham risk score modify family history ( double CV risk CV disease firstdegree relative 60 year age ) ; modify Framingham risk score take account age , HDLcholesterol , total cholesterol , systolic blood pressure , smoker status , presence diabetes family history CV disease normal 12lead electrocardiogram systolic blood pressure 105 130 mmHg diastolic blood pressure 60 90 mmHg supine heart rate 60 100 beat per minute evidence HIV infection ( ELISA test Western Blot ) , evidence hepatitis B virus infection ( HBsAg negative antiHBcAg negative HBsAg negative positive antiHBsAg positive antiHBcAg ) HCV infection screening ( antiHCV serology ) use effective barrier method contraception nonsmoker drink less 14 unit alcohol per week maximum 4 unit per day one unit alcohol correspond 341 mL standard beer 142 mL wine 43 ml spirit negative illicit drug test screening ; body mass index 18.0 30.0 kg/m2 age 18 50 year old volunteer must able understand comply protocol requirement willing sign inform consent form prior study procedure ; absence exclusion criterion . history postural hypotension cardiac disease acute chronic liver disease hepatic impairment acute chronic kidney disease renal impairment use prescription drug , counter drug , recreational drug , herbal dietary supplement include vitamin grapefruit juice within 15 day study initiation ( day 1 ) except acetaminophen and/or ibuprofen need basis . These product also prohibit study ( except need acetaminophen and/or ibuprofen ) subject receive experimental medication within last 2 month and/or donate blood previous 2 month intend donate blood within 2 month follow completion study also exclude ; subject unprotected sexual activity last 6 month new recent partner subject inject intravenous drug last 6 month subject social condition , psychological addictive disorder would impair protocol adherence .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>maraviroc</keyword>
	<keyword>boceprevir</keyword>
	<keyword>HIV</keyword>
	<keyword>HCV</keyword>
	<keyword>drug interaction</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>